智通财经6月15日电，永安药业(002365.SZ)公告称，近期公司股价短期涨幅较大，已严重偏离大盘走 势，存在较高的炒作风险。但公司基本面没有重大变化，也不存在应披露未披露的重大信息。2025年一 季度，公司处于亏损状态。根据中证指数有限公司的数据显示，截至本公告披露时，公司最新的静态市 净率、滚动市盈率、市净率均高于公司所属中上协行业分类"医药制造业"水平。公司已连续多日发布股 票交易异常波动公告，特别提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 永安药业：公司股价短期涨幅较大已严重偏离大盘走势 存在较高的炒作风险 ...

Core Viewpoint - Dongfulong Life Science Technology Co., Ltd. has applied for a patent for a single-stage and multi-stage mixer for microfluidic mixing, indicating its focus on innovation in pharmaceutical engineering technology [1] Company Overview - Dongfulong Life Science Technology Co., Ltd. was established in 2015 in Shanghai, primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 100 million RMB [2] - Dongfulong Technology Group Co., Ltd. was founded in 1993 in Shanghai, focusing on specialized equipment manufacturing, with a registered capital of approximately 765.83 million RMB [2] Patent Details - The patent application, published as CN120132922A, was filed on December 2023 and pertains to a microfluidic mixer designed to enhance the mixing effect of two-phase liquids and improve the quality of nanoparticle formation [1] - The mixer includes a diversion section, a convergence section, and at least one liquid level conversion section, which allows for the alteration of the boundary order of liquids to facilitate better mixing [1]

金融界 2025 年 6 月 14 日消息，国家知识产权局信息显示，南通立洋化学有限公司;南通醋酸化工股份 有限公司申请一项名为"一种 2-氰基吡啶的纯化方法"的专利，公开号 CN120136782A，申请日期为 2023 年 12 月。 南通醋酸化工股份有限公司，成立于1959年，位于南通市，是一家以从事化学原料和化学制品制造业为 主的企业。企业注册资本20738.1万人民币。通过天眼查大数据分析，南通醋酸化工股份有限公司共对 外投资了15家企业，参与招投标项目13次，财产线索方面有商标信息6条，专利信息173条，此外企业还 拥有行政许可25个。 专利摘要显示，本发明公开了一种 2‑氰基吡啶的纯化方法，属于化工技术领域。本发明 2‑氰基吡啶的 纯化方法包括：在以 2‑甲基吡啶为原料，氨氧催化制备 2‑氰基吡啶粗品过程中，将得到的 2‑氰基吡啶 粗品经过装有金属吸附剂的吸附柱进行吸附除杂，即得到纯品 2‑氰基吡啶；所述金属吸附剂为 Li、 Cs、Be、Rb 中的两种或多种金属与石墨烯复合而成。通过该方法能够将纯度为 99.8％的 2‑氰基吡啶提 纯至 99.99％，得到高品质的 2‑氰基吡啶，同时无需回流回流 ...

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. has received a debt waiver from nine bondholders, which significantly impacts its financial structure and ongoing restructuring efforts [1][2][3] Debt Waiver Details - The company has entered into a debt waiver agreement with nine bondholders, which includes a total waiver of 1.1 billion yuan in principal and all accrued interest and penalties, amounting to a total of 2.66 billion yuan [20][21] - The debt waiver is unconditional, irrevocable, and does not require any further internal approval processes [6][13][21] Financial Position - As of the waiver date, the company had outstanding debts of 294.64 million yuan in principal, 93.64 million yuan in interest, and 62.62 million yuan in penalties [6][7] - Following the debt waiver, the remaining debts will be 184.64 million yuan in principal, with no remaining interest or penalties [6][7] Fund Management and Relationships - The nine bondholders are managed by five fund management companies, which have confirmed that they have no relationships with the company, its controlling shareholders, or its executives [4][5][12] - The fund management companies have followed proper internal decision-making procedures regarding the debt waiver [5][12] Restructuring Process - The company is currently in a pre-restructuring phase, with the debt waiver not being a prerequisite for the restructuring process [13][20] - The restructuring efforts have led to a positive shift in the company's net assets, moving from negative to positive [20][22] Asset Management - The company has sold a low-efficiency asset, "Taihu Star," for 64.69 million yuan, which has improved its cash flow and reduced operational pressure [20][21] - The asset sale and debt waiver are part of a broader strategy to optimize the company's financial structure and improve operational capabilities [20][22]

Financial Performance - The company's revenue and net profit are expected to show growth in Q2 2025 compared to Q1 2025, with current order volumes meeting expectations [1] - Direct exports to the U.S. account for a low percentage of revenue, minimizing the impact of recent U.S. tariffs [1] - The company has faced a significant decline in net profit since its IPO, with the stock price currently less than one-third of the initial offering price of 50 CNY per share [2][3] Market Challenges - The stock price has been in a long-term decline, attributed to macroeconomic factors, market conditions, and industry developments [2][3] - The company’s internal value does not align with its market capitalization, facing issues such as insufficient information disclosure and a lack of recognized business logic [3] Product Development - The solid-state battery project has completed kilogram-level experiments and is currently in the process optimization phase, with no mass production yet [2][4] - The company is focusing on high-end raw materials and specialty intermediates in the pharmaceutical sector, aiming to expand its international market presence [4] Strategic Initiatives - The company plans to enhance its core competitiveness through improved main business operations and effective value communication to investors [2][3] - In the lithium battery materials sector, the company aims to reduce production costs through technological upgrades and expansion into upstream supply chains [4]

浩欧博发布异动公告，公司股票交易连续3个交易日内收盘价格涨幅偏离值累计达到30%，属于股票交 易异常波动情形。经公司自查并向控股股东、实际控制人核实，不存在应披露而未披露的重大信息。截 至2025年6月12日，公司收盘价为137.88元/股，最新市盈率为236.24倍，滚动市盈率为251.04倍，医药 制造业最近一个月平均滚动市盈率为28.07倍。公司特别提醒广大投资者，注意投资风险，理性决策， 审慎投资。 ...

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets have released important announcements, providing insights for investors [1] Company Announcements - JingJin Equipment's actual controller, chairman, and general manager has been detained and is under investigation, but the company's operations remain normal and unaffected [3] - XinBeiYang reported that its stock price has deviated significantly, but confirmed that its operations and external environment have not changed materially [4] - Jiuqi Co. announced a share transfer price of 14.62 yuan per share, with 2,330,880 shares fully subscribed by seven institutional investors [5] - Yuanlong Yatu confirmed that there are no undisclosed significant matters affecting its operations despite stock price fluctuations [6] - ST Xuefa stated that it maintains independence from related parties, ensuring that external matters do not adversely affect its operations [7] - Lao Feng Xiang plans to establish a wholly-owned subsidiary in Hong Kong with a registered capital of 200 million USD for overseas investments [8] - Youzu Network indicated that its convertible bonds may trigger redemption conditions based on stock price performance [9] - Xintian Pharmaceutical received a cash dividend of 15 million yuan from its wholly-owned subsidiary, which will increase its net profit for the parent company but not affect consolidated net profit [11] - Xiehe Electronics announced that two shareholders plan to reduce their holdings by a total of up to 88,000 shares [13] - China Power Construction's subsidiary won a 10.77 billion yuan EPC contract for an offshore wind power project, although the contract is not yet signed [15]

Group 1: Market Position and Strategy - The company has achieved large-scale production of steroid drug starting materials, ranking among the top globally in terms of production capacity and variety [2] - It has established a vertically integrated system covering the entire steroid drug industry chain, becoming a key R&D and production base for steroid drug intermediates in China [3] - The company focuses on three strategic directions: reducing production costs through technological iteration, optimizing existing production lines to increase high-value product capacity, and expanding market presence in emerging fields like anti-cancer and assisted reproduction [3] Group 2: R&D Investment and Achievements - R&D investments from 2022 to 2024 were 45.15 million, 38.10 million, and 51.08 million CNY, respectively, with the proportion of R&D investment to revenue increasing year by year [4] - The company has established a closed-loop innovation system from basic research to industrialization, recognized with multiple awards including the National Science and Technology Progress Award [3] Group 3: International Market Expansion - In 2024, the company's product export ratio was 28.54%, showing a year-on-year increase [3] - Plans for 2025 include strengthening brand promotion and sales channels through overseas subsidiaries and seeking commercial cooperation through international resources [3] Group 4: Stock Performance and Future Plans - The company is considering stock repurchase based on market conditions, with updates provided monthly [5] - There are ongoing projects for innovative drugs, including the industrialization of Vitamin D3, which is progressing as planned [5]

贵州三力（SH 603439，收盘价：12.34元）6月11日晚间发布公告称，截至本报告披露日，贵州三力制 药股份有限公司持股5%以上股东海南悦欣医药投资合伙企业（普通合伙）持有公司股份2100万股，占 公司总股本的约5.12%；公司副董事长、总经理、董事会秘书张千帆持有公司股份约71万股，占公司总 股本的0.1744%；公司董事、副总经理王毅持有公司股份约134万股，占公司总股本的0.3258%；公司副 总经理余渊持有公司股份约32万股，占公司总股本的0.0793%；公司副总经理罗战彪持有公司股份37万 股，占公司总股本的0.0903%。持股5%以上股东海南悦欣医药投资合伙企业（普通合伙）因自身业务需 求，拟从2025年7月3日至2025年10月2日期间，通过集中竞价交易方式减持其所持有的公司股份合计不 超过约205万股。公司副董事长、总经理、董事会秘书张千帆因个人资金需求，拟从2025年7月3日至 2025年10月2日期间，通过集中竞价交易方式减持其所持有的公司股份合计不超过约18万股。公司董 事、副总经理王毅因个人资金需求，拟从2025年7月3日至2025年10月2日期间，通过集中竞价交易方式 减持其所 ...

通过天眼查大数据分析，江苏吴中医药发展股份有限公司共对外投资了12家企业，参与招投标项目5 次，知识产权方面有商标信息47条，专利信息2条，此外企业还拥有行政许可9个。 资金流向方面，今日主力资金净流出2294.66万元，占比成交额19.03%。其中，超大单净流出796.05万 元、占成交额6.6%，大单净流出1498.61万元、占成交额12.43%，中单净流出流入480.73万元、占成交 额3.99%，小单净流入1813.93万元、占成交额15.04%。 来源：金融界 金融界消息 截至2025年6月11日收盘，*ST苏吴（600200）报收于2.63元，下跌1.13%，换手率6.41%， 成交量45.58万手，成交金额1.21亿元。 天眼查商业履历信息显示，江苏吴中医药发展股份有限公司，成立于1994年，位于苏州市，是一家以从 事医药制造业为主的企业。企业注册资本71215.1832万人民币，实缴资本12279.5762万人民币。公司法 定代表人为钱群山。 *ST苏吴最新一期业绩显示，截至2025一季报，公司营业总收入3.17亿元、同比减少25.44%，归属净利 润7031.79万元，同比减少1489.93 ...